Granted Patent B2

US 12,270,814 · App. 18/482,286 · Granted Apr 8, 2025

Inventors: Adi L. Tarca (South Lyon, MI); Piya Chaemsaithong (Shatin, HK); Tinnakorn Chaiworapongsa (Grosse Pointe Park, MI); Sonia S. Hassan (Novi, MI); Roberto Romero (Grosse Pointe, MI)

Assignees: Wayne State University; The United States of America, as Represented by the Secretary, Department of Health & Human Services

G01N33/689A61K35/16C12Q1/6883C12Q2600/158C12Y304/24007G01N2333/96494G01N2800/52

Abstract

Claims (30)

1. A method consisting of:

obtaining a plasma or serum sample derived from a pregnant human subject in the 22 nd to 28 th week of gestation; and

contacting the sample with at least two binding ligands in one or more wells, wherein at least one binding ligand binds biomarker Sialic acid-binding Ig-like lectin 6 (Siglec-6) and at least one binding ligand binds biomarker Activin A.

2. The method of claim 1 , wherein the contacting comprises loading samples into the one or more wells coated with Siglec-6 binding ligands; and the one or more wells coated with Activin A binding ligands.

3. A method consisting of:

obtaining a first plasma or serum sample derived from a pregnant human subject in the 22 nd to 28 th week of gestation;

contacting the first sample with at least two binding ligands, at least one of which binds biomarker Sialic acid-binding Ig-like lectin 6 (Siglec-6) and at least one of which binds biomarker Activin A;

obtaining a second plasma or serum sample derived from the pregnant human subject in the 28 th to 32 nd week of gestation; and

contacting the second sample with one or more binding ligands in one or more wells that bind a biomarker, the one or more binding ligands selected from

at least one ligand that binds biomarker Siglec-6,

at least one ligand that binds biomarker CD166 antigen (ALCAM), and

at least one ligand that binds biomarker Ficolin-2 (FCN2).

4. The method of claim 3 , wherein the

one or more wells are coated with at least one of Siglec-6 binding ligands,

ALCAM binding ligands, and

FCN2 binding ligands.

5. A method consisting of:

assaying a serum or plasma sample obtained from a pregnant human subject in the 22 nd to 28 th week of gestation for expression level of biomarker proteins Sialic acid-binding Ig-like lectin 6 (Siglec-6) and Activin A:

wherein the assaying comprises loading samples into one or more wells coated with binding ligands.

6. The method of claim 5 wherein at least one of the one or more wells coated with binding ligands is coated with

Siglec-6 binding ligands, and at least one of the one or more wells coated with binding ligands is coated with Activin A binding ligands.

7. A method consisting of:

assaying a first serum or plasma sample obtained from a pregnant human subject in the 22 nd to 28 th week of gestation for expression level of biomarker proteins Sialic acid-binding lg-like lectin 6 (Siglec-6) and Activin A;

assaying a second serum or plasma sample obtained from the pregnant human subject in the 28 th to 32 nd week of gestation for expression level of biomarker proteins Siglec-6, CD166 antigen (ALCAM), and Ficolin-2 (FCN2);

wherein the assaying of the second serum comprises loading the second sample into one or more wells coated with binding ligands.

8. The method of claim 7 wherein:

the

one or more wells are coated with binding ligands selected from: Siglec-6 binding ligands,

ALCAM binding ligands, and

FCN2 binding ligands.

Assignments (2)

Continuity (4)

References Cited (32)